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Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although
first described 60 years ago, only became the subject of interest after the turn of the millennium. In
2001, the World Health Organization (WHO) defined the classification of this group of diseases and
in 2008 they were renamed myeloproliferative neoplasms based on morphological, cytogenetic and
molecular features. In 2005, the identification of a recurrent molecular abnormality characterized
by a gain of function with a mutation in the gene encoding Janus kinase 2 (JAK2) paved the way for
greater knowledge of the pathophysiology of myeloproliferative neoplasms. The JAK2 mutation is
found in 90-98% of polycythemia vera and in about 50% essential thrombocytosis and primary
myelofibrosis. In addition to the JAK2 mutation, other mutations involving TET2 (ten-eleven
translocation), LNK (a membrane-bound adaptor protein); IDH1/2 (isocitrate dehydrogenase 1/2
enzyme); ASXL1 (additional sex combs-like 1) genes were found in myeloproliferative neoplasms
thus showing the importance of identifying molecular genetic alterations to confirm diagnosis, guide
treatment and improve our understanding of the biology of these diseases. Currently, polycythemia
vera, essential thrombocytosis, myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic
leukemia and mastocytosis are included in this group of myeloproliferative neoplasms, but are
considered different situations with individualized diagnostic methods and treatment. This review
updates pathogenic aspects, molecular genetic alterations, the fundamental criteria for diagnosis
and the best approach for each of these entities.
Keywords: Myeloproliferative disorders; Thrombocytosis; Polycythemia vera; Primary
myelofibrosis
Introduction
In 1951, William Dameshek was the first author to report on the clinical and
laboratory similarities of the four main hyperproliferative myeloid entities: chronic myeloid
leukemia (CML), polycythemia vera (PV), essential thrombocytosis (ET), and primary
myelofibrosis (PMF).(1) In 1975, the Group for the Study of Polycythemia Vera (PVSG)
defined the diagnostic criteria and classification of Philadelphia (Ph) chromosome
negative chronic myeloproliferative disorders. These parameters were redefined by
Pearson in 1996.(2)
In 2001, the World Health Organization (WHO) proposed a new classification of
these disorders, adding laboratory findings, imaging and evaluation of the bone marrow
as diagnostic criteria.(3)
In 2008, through advances in cytogenetics and molecular biology, myeloproliferative
disorders were renamed by the WHO as myeloproliferative neoplasms (MPN). In this
classification, new groups were added taking into consideration relevant aspects such as
clinical behavior, morphologic features, cytogenetics, and molecular changes.(4) Table 1
lists the diseases encompassed in the MPN group.
The WHO 2008 classification of MPN included bone marrow (BM) histology as a
diagnostic criterion as follows:(5)
– cellularity, maturation status, and topography of hematopoietic elements;
– morphology, arrangement and topography of megakaryocytes;
– evaluation of reticulin fibers, collagen deposits and hemosiderin contents;
– evaluation of anomalous infiltrating elements and atypically located blast
aggregates;
– cell histogenesis by immunohistochemistry, allied with morphological and
topographic evaluation;
– evaluation of CD34 and or CD117 expression by immunohistochemistry;
– presence of selected chromosome aberrations, by fluorescent in situ chromogenic
hybridization.
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Polycythemia vera
In the WHO 2008 classification of PV, a minor criterion
refers to the BM findings: "hypercellularity with trilineage
growth, prominent erythroid, granulocytic and megakaryocytic
proliferation". Neither iron-laden macrophages nor reticulin
fibers are conspicuous (increased 1+ or 2+ in less than 20%
of the cases). Megakaryocytic alterations are important to
distinguish PV from secondary polycythemia. In the
myelofibrotic stage, which occurs in around 30% of the
cases 10-12 years after diagnosis, it may be very difficult, if
not impossible, to distinguish this from primary myelo-
fibrosis.(6) [Table 2; Figure 1A & 1B]
Essential thrombocythemia
One of the four major criteria that define ET in the WHO
2008 classification is: "bone marrow biopsy showing
proliferation mainly of the megakaryocytic lineage with
increased numbers of enlarged, mature megakaryocytes. No
significant increase or left-shift of neutrophil granulopoiesis
or erythropoiesis". The nuclei of megakaryocytes are
hyperlobulated or intensely folded, dispersed or loosely
clustered. There is no or only a slight increase in reticulin
fibers. In follow-up biopsies, it was shown that increases of
reticulin fibers is indicative of progression to myelo-
fibrosis.(7,8) [Table 2; Figure 1C & 1D]
Primary myelofibrosis
PMF is characterized in the WHO 2008 classification
(major criterion) as: "presence of megakaryocyte proliferation
and atypia, usually accompanied by reticulin and/or collagen
fibrosis, or in the absence of significant reticulin fibrosis, the
megakaryocytic changes must be accompanied by an increased
bone marrow cellularity characterized by granulocytic
proliferation and often decreased erythropoiesis (i.e., prefibrotic
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cellular-phase disease). There may be a moderate increase in
reticulin fibers, but no collagen is seen. Megakaryocyte
alterations are rather discriminating: anomalous topography,
with prominent morphological abnormalities: pleomorphism,
aberration of the nuclear cytoplasmic ratio due to large, bulbous
and hyperchromatic cloud-shaped nuclei, disorganization of
nuclear lobulation, naked megakaryocytes and maturation
arrest. Early fibrosis leads to sinus dilatation as a result of
stromal retraction.(9) [Table 2; Figure 1E & 1F]
Cytogenetics
The identification of molecular genetic changes in
chronic MPN is important to confirm the diagnosis, direct
treatment, and improve our understanding of the biology of
a disease.
The karyotype provides a comprehensive assessment
of chromosomal abnormalities. It should be indicated
whenever there is suspicion of MPN with leukocytosis,
eosinophilia, monocytosis and/or thrombocytosis.(10) The
identification of the Ph chromosome [t(9;22)(q34,q11)] or its
variants confirm diagnosis of CML.(10) However, the
investigation should be extended in the presence of other
chromosomal abnormalities (Table 3).(1) The fluorescence in
situ hybridization (FISH) and molecular cytogenetic methods
are specific, sensitive and fast. These techniques have been
recommended for situations in which there is no metaphases
for analysis or in the absence of Ph karyotype.(11) In some
cases, the study of molecular mutations can be made by
polymerase chain reaction (PCR) or reverse transcriptase PCR
(RT-PCR). At the diagnosis of PV, 10 to 30% of karyotypes
are changed, but with the progression of the disease, the rate
of cytogenetic abnormalities affects over 80% of cases,
particularly in the fibrotic phase or at transformation to acute
leukemia after polycythemia.(12) Approximately 50 to 60% of
patients with PMF present altered karyotypes. Cases of ET
show a smaller percentage of abnormalities at diagnosis (Table
3).(11,12) But differentiation with myelodysplastic syndrome
(MDS) should be made with the identification of del(5q) and
t(3, 3)/inv(3).
Molecular aspects
The first clues to the understanding of molecular basis
of MPN were only revealed 50 years after Dameshek's
insights. In 2005, four groups, using different methodologies,
identified the first recurrent molecular abnormality in patients
with MPN - a gain-of-function mutation of the gene encoding
Janus kinase 2 (JAK2). The presence of the JAK2V617F
mutation distinguishes PV from secondary polycythemia.(13)
The JAK2V617F mutation has been found in 90-98% of PV
patients, in about 50% of those with ET or PMF, in some
patients with myelodysplastic/myeloproliferative neoplasms
and in rare cases of acute myeloid leukemia (AML). The
JAK2V617F mutation is a somatic guanine-to-thymine
substitution at nucleotide 1849 in exon 14 that results in a
valine-to-phenylalanine substitution in codon 617
(V617F).(14,15) JAK2 is a cytoplasmic tyrosine kinase that plays
a central role in signal transduction from multiple
hematopoietic growth factor receptors. It is associated with
a growth factor-independent phenotype, leading to abnormal
hematopoiesis.(15) Additionally, rare cases of MF and ET may
have a mutation in MPLW515K/L.
Figure 1 – Histological features of chronic myeloproliferative
neoplasms
A & B: Polycythemia Vera - Hypercellular bone marrow with increased
numbers of erythroblasts and pleomorphic megakaryocytes (A:
hematoxylin and eosin - magnification 200 x). Megakaryocytes show
hyperlobated nuclei and are arranged in loose clusters (B: hematoxylin
and eosin - magnification 1000 x)
C & D: Essential thrombocythemia - No significant alterations of the
myeloid and erythroid series. Megakaryocytes are significantly
increased in number, show hyperlobated nuclei and are isolated or
arranged in loose clusters (C: hematoxylin and eosin - magnification
1000 x). Reticulin fibers are present in a loose network with some
intersections (D: Gomori argentic impregnation - 1000 x)
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In MPN, the presence of JAK2V617F has been
associated with higher hemoglobin level, higher leukocyte
count and lower platelet count.(16) In PV, a higher JAK2V617F
allele burden has been associated with pruritus and
transformation into myelofibrosis, but it does not seem to
affect the risk of thrombosis, leukemic transformation or
survival.(16) In patients with ET, JAK2V617F does not appear
to be related with survival or leukemic transformation, but its
association with thrombotic events is controversial. In PMF,
a lower mutant allele burden has been associated with a lower
survival rate.(17) The intriguing fact that a few PV patients
and almost half of those with ET and PMF do not have the
JAK2V617F mutation has prompted interest in studying other
candidate genes that could be involved in the pathogenetic
mechanisms of JAK2V617F-negative MPN.
These studies led to the discovery of JAK2 exon 12
mutations in ~3% of JAK2V617F-negative PV patients;
thrombopoietin receptor gene (MPL - Myeloproliferative
leukemia virus oncogene) mutations in ~8.5% of ET and 10%
of PMF patients and TET2 (TET oncogene family member 2)
gene mutations in ~ 16% of PV, 5% of ET and ~17% PMF
patients.(18)
More recently, other mutations involving LNK (a
membrane-bound adaptor protein), IDH1/2 (isocitrate
dehydrogenase 1/2 enzyme), ASXL1 (additional sex combs-
like 1), CBL (casitas B-lineage lymphoma proto-oncogene),
IKZF1 (IKAROS family zinc finger 1) and EZH2 (an histone




ET is a clonal disorder. It is characterized by
megakaryocytic proliferation with consequent increased
peripheral platelets. Its course is chronic and may progress
to myelofibrosis or acute leukemia.(20)
Epidemiology
The incidence varies between 0.6 to 2.5 cases per
100,000 persons/year. It is a disorder of middle age and is rare
in childhood (one case per one million children).(21) It is
predominant in females (2:1). There is possibly family
involvement.
Clinical features
Vasomotor symptoms predominate: headache,
dizziness, tinnitus, syncope, tingling, visual changes,
acrocyanosis or erythromelalgia, translated as burning
sensation in the feet and hands associated with redness and
warmth. Between 25 to 35% of patients are asymptomatic
and discover thrombocytosis accidentally. Mild
splenomegaly is found in up to 40%. When platelets exceed
1000 x 109/L, there is increased risk of spontaneous bleeding
in the gastrointestinal tract.(22) Bleeding and thrombotic
events, the last represented by deep vein thrombosis,
pulmonary embolism or Budd-Chiari syndrome, are
responsible for morbidity and mortality. It is important to
remember that angina, myocardial infarction, transient
ischemic attack (TIA), stroke, pulmonary embolism or priapism
can be the first manifestation of thrombocytosis.
Pathophysiology
For decades, ET was attributed to the proliferative
advantage of megakaryocytic factors related to thrombopoietin
(TPO) and its cellular receptor (c-Mpl). The mutations
involved in MPN start early in the stem cell. Megakaryocytic
precursors are hypersensitive to TPO and the action of
cytokines: TGF beta, Interleukins 3 (IL-3), IL-6 and IL-11,
which interact with the bone marrow microenvironment,
promoting the growth of megakaryocytes.(23) In 35 to 70% of
cases, acquired somatic mutation occur in the Janus kinase
gene 2(JAK2V617F), responsible for phosphorylation and
signaling activators of transcription (STAT). Three novel
somatic mutations in the juxtamembrane region at codon 515
MPL (W515L, W515K, S505N) explain defects in signaling
pathways of molecules STAT3, STAT5, mitogen activator
protein (MAPK) and phosphatidylinositol-3kinase ATK
(PI3K/AKT), giving a gain in function and proliferative
advantage to megakaryocytes.(23)
Diagnostic criteria
WHO 2008 and British Committee for Standards in
Hematology 2010(24)
Requires A1-A4
A1) platelet count > 450 x109/L sustained over more
than six months without apparent cause;
A2) bone marrow biopsy: megakaryocytic hyper-
proliferation, in which megakaryocytes are increased in
number and size with mature hyperlobulated and grouped.
A3) Absence of WHO criteria for CML, PV (normal red
cell mass), PMF (no fibrosis), del 5q, MDS
A4) MPL and JAK2 mutations positive; if negative, no
evidence for reactive thrombocytosis
British Committee for Standards in Hematology (BCSH)
2010
Requires A1-A3 or A3 + A3-A5
A.1) platelet count > 450 x109/L sustained over more
than six months without apparent cause
A.2) JAK2 mutations and MPL positive
A.3) Absence of WHO criteria for CML, PV (normal red
cell mass), PMF (no fibrosis), del 5q, MDS
A.4) no evidence of reactive thrombocytosis and normal
iron stores
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A.5) bone marrow biopsy: megakaryocytic proliferation
with megakaryocytes increased in number and size,
hyperlobulated with abundant cytoplasm.
Differential diagnosis
ET must be distinguished from other MPN and the
processes that lead to transient reactive thrombocytosis:
acute hemorrhage, recovery of thrombocytopenia, infections,
inflammatory diseases, tissue damage, iron deficiency,
hemolytic anemia, post splenectomy, cryoglobulinemia,
medications (steroids, adrenaline, trans-retinoic acid),
neoplasms, myelodysplasia Del 5q.
Risk stratification
Risk stratification considering the possibility of
thrombosis. Several retrospective and prospective studies
have shown two major factors for vascular complications: 1)
age over 60 years and 2) previous thrombotic events. The
platelet count above 1500 x 109/L, is associated with acquired
von Willebrand disease, linked to risk of bleeding.(20,23)
Patients with ET are divided into risk groups:
High risk
– Age > 60years
and/or
– Episodes of bleeding or prior thromboembolic
phenomena and/or
– Platelet count > 1500 109/L
Intermediate risk
– Age > 40 and < 60 years
– Presence of cardiovascular risk factors (smoking,
hypertension, dyslipidemia, diabetes)
– Platelet count less than 1500 x 109/L
This group is still discussed and is not universally
accepted.
Low risk
– Age < 40 years
– No previous thromboembolic phenomena
– No risk factors
– Platelet count < 1500 x 109/L
Over the past two years, meta-analyses have included
the JAK2 and/or
 Leukocytosis > 10 x 109/L as higher risk for thrombosis
in ET(25)
Management
Conducts aim to prevent major bleeding and
thrombosis, without increasing the risk of transformation to
myelofibrosis or AML.(26)
Low Risk: the recommendation in asymptomatic
patients is observation "watch and wait" (evidence - grade
B). Some studies have suggested that aspirin prevents
thrombotic complications and decreases microvascular
disorders such as erythromelalgia, acrocyanosis, headache,
dizziness, visual disorders and paresthesia of the extremities
(palms and soles).(25) However, there is lack of evidence that
it has effective prophylactic effects.
Intermediate risk: the therapy should be individualized.
Platelets > 600 x 109/L in the presence of cardiovascular
factors: Aspirin 100 mg/day and/or thrombocythemia reducing
agents (evidence - grade C).(27) There is no consensus on
what the best approach should be to patients younger than
60 years of age, platelet counts of less than 1000 x 109/L but
greater than 600 x 109/L, no history of vasomotor and/or
thrombohemorrhagic phenomena, but in the presence of
cardiovascular factors.
High Risk: Patients over 60 years, platelets 600 x 109/L
in the presence of cardiovascular risk factors are candidates
for therapy. The first line is Hydroxyurea (HU) at an initial
dose of 15 mg/kg/day in order to reduce the platelet count to
less than 450 x 109/L.(28) Patients with indication for
cytoreduction, but who fail HU therapy due to intolerance or
resistance, should migrate to second-line therapy, where
anagrelide and interferon alpha are utilized.(29)
Hematopoietic stem cell transplantation (HSCT) is not
part of the conventional therapies for ET. However,
allogeneic HSCT can be recommended in patients aged < 60
years old, with transformation to myelofibrosis or acute
leukemia.(30)
JAK2 inhibitors are being tested in ET, but their benefits




PMF has a heterogeneous clinical presentation. Around
30% of the patients are asymptomatic and present spleno-
megaly on physical exam or have a routine blood analysis that
shows anemia, leukocytosis and/or thrombocytosis. In the
initial phase, PMF may resemble ET because the initial finding
may be only thrombocytosis. Patients also may present
constitutional symptoms such as dyspnea, fatigue, night
sweats, weight loss, fever, and bleeding. Some patients present
renal stones and gouty arthritis due to hyperuricemia.
Splenomegaly is present in 90% of the cases.(32)
Epidemiology and etiology: the disease occurs in 0.5-
1.5 cases per 100,000 people per year, most commonly in the
sixth or seventh decades of life and affecting both genders.
Exposure to benzene or ionizing radiation is present in some
cases and rare familial cases have been documented.(32)
The initial mutation responsible for PMF is not known.
However, the majority of patients present JAK2V617F and
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a minority present MPL, LNK, CBL, TET2, ASXL1, IDH, IKZF1
or EZH2 mutations.(18) The JAK2V617F mutation is present
in approximately 50-65% of the cases. Besides the clonal
myeloproliferation present in PMF, a secondary inflammatory
state occurs, characterized by bone marrow stromal changes
and abnormal cytokine expression. Plasma levels of
proinflammatory cytokines are elevated in PMF and might be
pathogenetically linked to disease-associated constitutional
symptoms and cachexia and also related to worse overall
(OS) and leukemia-free survival (LFS).(33)
Diagnosis and classification
PMF is classified as a clonal BCR-ABL negative MPN
by the WHO classification.(32) Diagnosis is based on findings
of physical exam, peripheral blood, bone marrow morphology,
cytogenetics and molecular markers and exclusion of other
diseases (Table 4). The typical peripheral blood smear shows
leukoerythroblastosis and anisopoikilocytosis with teardrop-
shaped red cells. The disease may be diagnosed in a
prefibrotic stage (early stage) or more frequently, in an over
fibrotic stage.(34)
Differential diagnosis
Includes bone marrow fibrosis associated with non-
neoplastic or other neoplastic conditions, such as metastatic
cancer, lymphoid neoplasm and other myeloid malignancies,
especially CML, MDS, chronic myelomonocytic leukemia
(CMML), or AML.
Risk stratification
Accurate risk stratification of patients in terms of OS
and LFS is necessary for treatment decisions regarding the
timing for allogeneic transplantation, palliative treatment or
participation in clinical trials.
The International Working Group for Myelofibrosis
Research and Treatment (IWG-MRT developed the
International Prognostic Scoring System (IPSS)(35) best used
for assessing survival at diagnosis. Subsequently, the same
group developed the dynamic IPSS (DIPSS)(36) model, which
can be used for estimating survival at any point in the disease
course. DIPSS also predicts the risk of progression to AML
in PMF. More recently, the DIPSS plus model included red
cell transfusion need,(37) unfavorable karyotype (+8, -7/7q,
i(17q), -5/-12p-, inv(3), 11q23) or complexes ≥ 3)(38) and
thrombocytopenia.
Treatment and role of bone marrow
transplantation
Currently there is no curative treatment for PMF with
the exception of bone marrow transplantation. However, this
approach is restricted to a few patients, considering the
morbidity and mortality of the procedure in this disease.
1) Treatment in low or intermediate 1 risk disease
For these patients with a long life expectancy (6-15
years) BMT is not justified. If the patient is symptomatic,
conventional drugs such as hydrea or interferon should be
used to control splenomegaly, leukocytosis and
thrombocytosis.(33)
2) Treatment in high or intermediate 2 risk disease
These patients can be treated with conventional drug
therapy, splenectomy, radiotherapy, allogeneic stem cell
transplantation (aSCT) or experimental drug therapy. The
main objective is to control anemia, symptomatic
splenomegaly, constitutional symptoms and disease
complications from extra medullary hematopoiesis (EMH).
Erythropoiesis stimulating agents (ESA) can be used
in patients with hemoglobin (Hb) < 10 g/dL, not transfusion
dependent, with erythropoietin levels < 125 U/L. Patients
that fail this approach or who are not candidates for ESA can
be treated with steroids, androgens, danazol, thalidomide (50
mg/d) with or without prednisone (0.25 mg/d) or lenalidomide
(10 mg/d) with or without prednisone. Response rates and
durations for each one of these treatment modalities are
similar.(33) Aspirin should be given to patients with a platelet
count of > 500 x 109/L due to the risk of thrombosis during
thalidomide or lenalidomide use.
Splenectomy can be indicated for drug-refractory
splenomegaly (more than 10 cm from the left costal margin) in
symptomatic and transfusion dependent patients.(39) However,
splenectomy has a perioperative mortality rate of 5-10% and
25% of morbidity with abdominal vein thrombosis, operative
site bleeding and infections. The median survival after
splenectomy is around two years. The hepatomegaly that
occurs in ~20% of patients after splenectomy can be treated
with hydroxyurea, cladribine or JAK inhibitors. Low-dose
radiotherapy (100 cGy in 5-10 fractions) can induce a transient
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(3-6 months) reduction in spleen size however, this is often
associated with severe and protracted pancytopenia.(40)
Role of bone marrow transplantation
BMT is the only curative option for PMF, but it is
associated with high morbidity and mortality. Taking all the
risks into consideration, BMT should not be indicated for
low or intermediate-1 risk disease.(41)
New drugs in clinical trials
The discovery of the activating mutation JAK2 (V617F),
present in more than 70% of patients with MPNs led to the
development of new biochemically selective JAK2 inhibitors.
JAK2 inhibitors are not specific for the JAK2V617F protein.
They inhibit the JAK2-signal transducer and STAT pathway
and can be used for any patient with MPN independent of
JAK2 mutational status. In PMF these agents have decreased
pathologic splenomegaly and improved disease-associated
symptoms.
 However, the ability of these agents to significantly
impact disease-associated cytopenias, JAK2 allele burden
or bone marrow histologic features remains unclear. Longer
follow-ups are needed to evaluate the long-term safety
profile.(42,43)
Polycythemia vera
PV is a pathologic condition presenting an increase of
red blood cells as a result of the autonomous and clonal
proliferation of bone marrow stem cells. Described for the
first time by Vaquez(44) in 1892 and singled out as a clinical
entity by Osler in 1903,(45) it was considered a slow but fatal
disease up to a few years ago. However, in the last decade,
changes in the physiopathologic criteria and the identification
of the JAK2 protein mutation (JAK2V617F) led the way to
diagnostic advances, better risk classification and the
development of new therapies.
Clinical findings
Signs and symptoms of PV are caused by a higher
erythrocytic load, leading to increases in blood viscosity
and as a consequence to the decrease of its flow. It is seen in
middle age individuals who characteristically present a
cyanotic blush, more easily seen in the face, mainly lips, nose
tip and ears. The same color alteration is also found in the
distal portion of the limbs.
Increased blood pressure is frequently found in PV and
this disease may be the cause of imbalance in the arterial
hypertension. Common complaints are headaches, tinnitus,
paresthesia and erythromelalgia which are related to the vaso-
occlusive phenomena. Pruritus may occur after a hot or tepid
baths and there can be some exacerbation of gout.(27) All of
these symptoms tend to improve or disappear with treatment.
The majority of patients present splenomegaly of varying
degrees at diagnosis or during the evolution of the disease.
They complain about feeling early satiety, increased
abdominal volume, left hypochondriac pain or bowel
constipation.
Epistaxis and ecchymosis are common. Ischemic
manifestations of the central nervous system (CNS) are
potentially debilitating and should be feared. Thrombosis
may occur at any arterial or venous site, but thrombosis in
the splanchnic territory are frequently related to MPNs which
should always be investigated.(46,47)
Pathophysiology
The description of JAK2V617F, present in 95% of cases
of PV, led to great advances in the understanding of its
pathogenesis. This mutation is not exclusive to this entity;
however, in PV there is a greater rate of homozygosis and a
higher allele burden compared to ET and PMF(48,49). Other
mutations were described but the one found in JAK2 exon 12
occurs in up to 2% of V617F negative patients.(49)
The natural evolution of PV is bone marrow fibrosis
and extramedullary hematopoiesis while there is a low
incidence of progression to myelodysplasia or acute
leukemia.
Diagnosis
Currently, the diagnosis is based on the British
guidelines(24) and on the World Health Organization (WHO)
2008 criteria(50) and requires the integration of clinical,
laboratorial, and histology factors (Table 5). These are
important points for proving the hematic changes by
measurements of the erythrocytic mass and Hb, as well as
demonstrating the presence of JAK2V617F or other mutations
having a similar function.
The bone marrow is hypercellular in all sectors, mainly
in the erythrocytic and megakaryocytic lineages. Erythroid
and myeloid precursors are morphologically normal whereas
megakaryocytes may present in loose and hyperlobulated
groups located close to the bone trabecula.
The requirement is the presence of both major criteria
and at least one of the minor ones, or the first major criterion
associated to two minor criteria.
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Compliance to these parameters discards other
pathologies presenting secondary polyglobinulemia, as
pulmonary fibrosis, cyanotic cardiopathy or chronic
obstructive pulmonary disease (COPD)
Risk stratification
Risk stratification is based on the probability of a
thrombotic event. Several studies identified age over 60 years
and earlier thrombosis as high risk predictors,(51) whereas their
absence is classified as low risk. Cardiovascular risk factor
and leukocytosis(52) seem to have some influence and may be
considered as average risk.
Treatment
The goal of the therapy is to control the hematocrit
level and decrease risk of morbidity. At the moment, it is still
not possible to clearly define a safe hematocrit level(51)
however, according to current guidelines,(53) the aim should
be to keep it below 45%. All patients benefit from the use of
low dose aspirin, as shown by the ECLAP study; low risk
patients should be managed with phlebotomy.
Cytoreducing is indicated for high risk patients or for
those who do not tolerate phlebotomy. Findings of
progressive myeloproliferation with leak or thrombocytosis,
symptomatic splenomegaly, pruritus or constitutional
symptoms also stress the need of cytoreduction.
The first line drug is hydroxyurea (HU).(54) The initial
dose varies from 500 to 1000 mg/d with later drug adjustment
for each patient. In general, it is well tolerated, but may present
some side effects such as cytopenia, gastrointestinal tract
symptoms, mucocutaneous ulcers, alopecia and fever. The
association with phlebotomy is possible when there is
limitation to dose augmentation due to cytopenias.
Interferon alpha, which has not been approved for this
indication by some health agencies yet, including the Food
and Drug Administration of the USA (FDA) or the European
Medicines Agency (EMA), has shown excellent response
with both conventional and pegylated forms, the latter has
greater tolerability. This drug is also indicated for pregnant
patients as it does not present any risk to the fetus.
Although JAK2 inhibitors are being tested in PV, they
are better indicated for the myelofibrosis phase for there is
no evidence of changes in the evolution of the disease.
There is also great interest in the histone deacetylase
inhibitors (HDAC)(55) vorinostat and givinostat; however,
further studies are required to attest their effectiveness and
safety.
Chronic neutrophil leukemia
It is a rare disease characterized by neutrophilia in the
peripheral blood and BM in the absence of Ph or BCR-ABL1
rearrangement.(56)
Clonal eosinophilia is defined according to the
pathophysiological characteristics or associated molecular
genetic changes as myeloid or lymphoid neoplasms with
eosinophilia and abnormalities of PDGFR alpha, PDGFR beta
or FGFR1.(57,58) They are characterized by myeloid or
lymphoproliferation thus manifesting chronic eosinophilic
leukemia (CEL), AML or lymphoma with persistent
eosinophilia usually > 1500/µL, organ infiltration by
eosinophils or mast cells, the presence of rearrangements
involving PDGFRalfa, PDGFRbeta or FGFR1, absence of Ph
or BCR-ABL1 rearrangements and < 20% blasts in BM(57,58).
CEL is more common in men with a peak incidence around 40
years. About 10% of patients are asymptomatic. In others,
symptoms such as fever, fatigue, cough, angioedema, muscle
aches, rash and diarrhea are frequent, as well as anemia,
thrombocytopenia, mucosal ulceration, endomyocardial
fibrosis and splenomegaly.(59)
We must distinguish CEL clonal hematopoietic diseases
in which eosinophilia is part of the neoplastic clone, such as
CML, PV, PMF and ET, MDS and AML, especially
myelomonocytic with inv(16) or the CBFβ/MYH11
rearrangement and maturation with t(8;21) or ETO/AML1
rearrangement (RUNX1/RUNXT1).(59) Clonal unspecified
chronic eosinophilia is characterized by a persistently high
number of eosinophils in peripheral blood (> 1500/µL), organ
and endomyocardial fibrosis, presence of blasts in BM or
peripheral blood (< 20%), absence of MPN or other evidence
of MDS, the absence of Ph (BCR/ABL1), PDGFRα, PDGFRβ,
FGFR1, inv(16), t(16,16) or t(5,12). Idiopathic hyper-
eosinophilic syndrome is similar to the above but without
the presence of blasts, without clonality and more than 6
months of eosinophilia.(56)
Mastocytosis
Mastocytosis is due to clonal proliferation of mast cells
that accumulate in different organs such as the bone marrow,
gastrointestinal tract, liver, spleen and lymph nodes. The
disease is heterogeneous, varying from itchy skin lesions
that can regress spontaneously to widespread and aggressive
infiltration with general symptoms. It can occur at any age. It
is classified according to the distribution: cutaneous form,
indolent systemic disease associated with clonal hematologic
damage, systemic aggressive mast cell leukemia, mast cell
and mast cell extracutaneous sarcoma.(59) Most adults with
mastocytosis present point mutations in c-KIT which
consists in the substitution of valine for aspartic acid
(ASP816VAL or D816V) in mononuclear cells of bone
marrow.(59)
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